Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor–Positive Breast Cancer

James R. Whittle,François Vaillant,Elliot Surgenor,Antonia N. Policheni,Göknur Giner,Bianca D. Capaldo,Huei-Rong Chen,He K. Liu,Johanna F. Dekkers,Norman Sachs,Hans Clevers,Andrew Fellowes,Thomas Green,Huiling Xu,Stephen B. Fox,Marco J. Herold,Gordon K. Smyth,Daniel H.D. Gray,Jane E. Visvader,Geoffrey J. Lindeman

DOI: https://doi.org/10.1158/1078-0432.ccr-19-1872

IF: 13.801

2020-04-03

Clinical Cancer Research

Abstract:PURPOSE: Although cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors significantly extend tumor response in patients with metastatic estrogen receptor-positive (ER⁺) breast cancer, relapse is almost inevitable. This may, in part, reflect the failure of CDK4/6 inhibitors to induce apoptotic cell death. We therefore evaluated combination therapy with ABT-199 (venetoclax), a potent and selective BCL2 inhibitor.EXPERIMENTAL DESIGN: BCL2 family member expression was assessed following treatment with endocrine therapy and the CDK4/6 inhibitor palbociclib. Functional assays were used to determine the impact of adding ABT-199 to fulvestrant and palbociclib in ER⁺ breast cancer cell lines, patient-derived organoid (PDO), and patient-derived xenograft (PDX) models. A syngeneic ER⁺ mouse mammary tumor model was used to study the effect of combination therapy on the immune system.RESULTS: Triple therapy was well tolerated and produced a superior and more durable tumor response compared with single or doublet therapy. This was associated with marked apoptosis, including of senescent cells, indicative of senolysis. Unexpectedly, ABT-199 resulted in Rb dephosphorylation and reduced G₁-S cyclins, most notably at high doses, thereby intensifying the fulvestrant/palbociclib-induced cell-cycle arrest. Interestingly, a CRISPR/Cas9 screen suggested that ABT-199 could mitigate loss of Rb (and potentially other mechanisms of acquired resistance) to palbociclib. ABT-199 did not abrogate the favorable immunomodulatory effects of palbociclib in a syngeneic ER⁺ mammary tumor model and extended tumor response when combined with anti-PD1 therapy.CONCLUSIONS: This study illustrates the potential for targeting BCL2 in combination with CDK4/6 inhibitors and supports investigation of combination therapy in ER⁺ breast cancer.

oncology